FIELD: pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to a soft hemostatic dosage form. Composition contains epsilon-aminocaproic acid in amount of 5.0 g, iron III chloride – 2.0 g; iron Fe3O4 or FeC nanoparticles – 0.1 g, active ingredient and polyethylene glycol-400 – 74.40 g and polyethylene glycol-1000 – 18.60 g as an ointment base.
EFFECT: invention provides a wider hemostatic arsenal.
1 cl, 3 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
MILD DOSAGE FORM FOR TREATING ONCOLOGICAL DISEASES | 2020 |
|
RU2743342C1 |
HAEMOSTATIC POLYMER-BASED AGENT CONTAINING MICROPARTICLES AND IRON OXIDE NANOPARTICLES, AND METHODS FOR PREPARING PHARMACOLOGICAL FORMS THEREOF | 2020 |
|
RU2739490C1 |
SOFT DOSAGE FORM | 2016 |
|
RU2647431C1 |
TOPICAL COMBINED HEMOSTATIC PREPARATION | 2012 |
|
RU2519026C2 |
BIODEGRADABLE HAEMOSTATIC THERAPEUTIC AGENT FOR CONTROL OF CAPILLARY AND PARENCHYMATOUS BLEEDINGS | 2013 |
|
RU2522879C1 |
HEMOSTATIC SPONGE (VERSIONS) | 2016 |
|
RU2627855C1 |
AGENT FOR PYOINFLAMMATORY PROCESSES IN SOFT TISSUES AND MUCOUS MEMBRANES | 2017 |
|
RU2641095C1 |
NANOMATERIAL FOR TARGETED DELIVERY OF ANTICANCER AGENTS AND ANTICANCER AGENTS BASED ON IT | 2016 |
|
RU2610170C1 |
HAEMOSTATIC MEDICATION BASED ON SYNTHETIC TRIPEPTIDE PLASMIN INHIBITOR | 2014 |
|
RU2550945C1 |
WOUND HEALING OINTMENT AND METHOD FOR ITS PRODUCTION | 2021 |
|
RU2791374C1 |
Authors
Dates
2020-01-17—Published
2019-07-03—Filed